We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Edico Genome, Amazon Web Services Partner
News

Edico Genome, Amazon Web Services Partner

Edico Genome, Amazon Web Services Partner
News

Edico Genome, Amazon Web Services Partner

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Edico Genome, Amazon Web Services Partner"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Edico Genome has announced that they are deploying DRAGEN on AWS’ newly available Amazon EC2 F1 instances, which are Field Programmable Gate Array (FPGA)-enabled instances in the cloud, potentially reducing analysis times from 26 minutes for a whole genome to real time. “DRAGEN customers appreciate that Edico continues to break new ground to make genomic analysis as rapid as technology allows. With AWS’ newest FPGA-based instances, DRAGEN will be able to analyze whole genomes in almost real time, which is unprecedented and would be a world first,” said Pieter van Rooyen, Ph.D., chief executive officer of Edico Genome.

“We look forward to offering a secure, highly scalable, and cost-efficient platform for genomic analysis to Edico customers, hospitals, academic institutions, drug developers, sequencing centers and others advancing genomic-based work.” A cloud configuration provides users with the flexibility to scale up to the cloud during times of high capacity and return to onsite analysis when demand is reduced.

The platform is compliant with the Health Insurance Portability and Accountability Act, regulations developed by the U.S. Department of Health and Human Services to protect the privacy and security of patients’ health information. Onsite analysis is also feasible, with both systems managed through the DRAGEN web portal, featuring an easy-to-use graphical user interface. Pipelines are identical whether executed in the cloud or onsite.

DRAGEN is highly reconfigurable, using FPGA to provide hardware-accelerated implementations of genome pipeline algorithms, such as BCL conversion, compression, mapping, alignment, sorting, duplicate marking, and haplotype variant calling. The flexible DRAGEN platform allows Edico to develop custom algorithms as well as refine and improve existing pipelines.

The following end-to-end, clinical-grade pipelines are currently available on the DRAGEN platform: genome/exome, transcriptome/RNA-seq, epigenome/methyl-seq, metagenome/microbiome, joint genotyping and GATK 3.6. Updated versions are made available for customers through regular, simple remote downloads. Pricing for the DRAGEN cloud solution on AWS will be announced by year end.

Source: Story from Edico Genome. Please note: The content above may have been edited to ensure it is in keeping with Technology Networks' style and length guidelines.

Advertisement